Amylin Pharmaceuticals and Takeda Pharmaceutical Company have suspended clinical activities in an ongoing Phase II study evaluating pramlintide/metreleptin for the treatment of obesity to investigate a new antibody-related laboratory finding.

The clinical study was designed to evaluate the safety and effectiveness of the investigational combination therapy.

Amylin Pharmaceuticals senior vice-president and chief medical officer Orville Kolterman said the safety of patients in the clinical programmes is of paramount concern to the companies.

“We have taken this precaution so that we can thoroughly investigate this finding,” Kolterman added.